Rosacea Diagnosis and Management

Pathophysiology and Clinical Features

Rosacea results from dysregulation of both innate and adaptive immune systems, with neurovascular abnormalities driving the characteristic centrofacial erythema and inflammatory features, according to the American Academy of Dermatology 1
The underlying mechanisms include immune dysregulation with CD4+ T lymphocytes, macrophages, mast cells, and dendritic cells forming the inflammatory infiltrate, as stated by the National Institute of Health 2
Elevated antimicrobial peptides, neuropeptides, and nitric oxide radical species perpetuate inflammation, contributing to the development of rosacea, as reported by the American Academy of Dermatology 1
Trigger factors such as Demodex mites and ultraviolet radiation activate inflammatory pathways, leading to rosacea symptoms, according to the British Journal of Dermatology 1

Persistent centrofacial erythema with periodic intensification by trigger factors is the minimum diagnostic feature of rosacea, as defined by the National Rosacea Society and the British Journal of Dermatology 3, 1
Phymatous changes alone are independently diagnostic of rosacea, characterized by skin thickening from sebaceous gland hyperplasia, according to the American Academy of Dermatology and the British Journal of Dermatology 3, 1, 2
Flushing, telangiectasia, and inflammatory papules/pustules alone are NOT diagnostic of rosacea, as stated by the National Institute of Health and the British Journal of Dermatology 3, 1
Psoriasis can be differentiated from rosacea by the presence of scale, extensor surface predilection, and well-demarcated plaques with silvery scale, as reported by the American Academy of Dermatology 1
Tinea corporis can be distinguished from rosacea by the presence of scale, annular configuration with central clearing, and positive KOH preparation for fungal elements, according to the National Institute of Health and the British Journal of Dermatology 1, 2

The British Journal of Dermatology recommends a phenotype-based approach to assess each feature independently, allowing for personalized treatment targeting specific manifestations 3, 1
Topical therapies such as ivermectin, azelaic acid, and metronidazole are effective for inflammatory papules/pustules, while brimonidine gel is used for persistent erythema, as reported by the American Academy of Dermatology and the National Institute of Health 1
Oral antibiotics like doxycycline and minocycline can be combined with topical therapy for moderate-to-severe disease, according to the American Academy of Dermatology 1
Procedural interventions such as pulse dye lasers, intense pulsed light, electrosurgery, dermabrasion, and surgical resurfacing are used for persistent erythema, telangiectasia, and phymatous changes, as stated by the National Institute of Health and the British Journal of Dermatology 1, 2

The American Academy of Dermatology emphasizes the importance of lifestyle modifications, including trigger avoidance, sun protection, and gentle skincare, to manage rosacea symptoms and prevent exacerbations 1
Patients should be educated about the chronic nature of rosacea, the importance of consistent treatment adherence, and the potential impact on quality of life, as reported by the National Rosacea Society and the British Journal of Dermatology 3, 1
The British Journal of Dermatology recommends considering psychological support if the disease significantly affects self-esteem or social functioning 3, 1

Topical ivermectin is recommended as the first‑choice agent for mild‑to‑moderate inflammatory papules and pustules. 4
Topical azelaic acid provides an equally effective alternative to ivermectin for the same phenotype. 4
Topical metronidazole is an additional option for mild‑to‑moderate inflammatory lesions when ivermectin or azelaic acid are unsuitable. 4
For moderate‑to‑severe papulopustular rosacea, a 6‑week course of oral doxycycline 40–100 mg twice daily combined with topical therapy is advised. [4][5]
Doxycycline 40 mg has demonstrated superiority over placebo and non‑inferiority to the higher 100 mg dose, supporting its use as the lower‑dose regimen. 4
Oral minocycline 50 mg twice daily or oxytetracycline 500 mg twice daily are acceptable alternatives when doxycycline cannot be used. 5
Topical brimonidine (an α‑adrenergic agonist) is effective for symptomatic control of persistent facial erythema (flushing). 4
Oral β‑blockers may be considered in patients with frequent flushing episodes. 4
Pulsed‑dye laser (PDL) or intense pulsed light (IPL) are recommended for cases resistant to medical therapy. 4

Daily broad‑spectrum sunscreen (SPF 30 or higher) should be applied to mitigate UV‑induced inflammatory pathways. 4
Gentle, alcohol‑free cleansers and moisturizers are advised to maintain barrier integrity. [4][5]
Patients should avoid known trigger factors such as hot beverages, spicy foods, alcohol, and extreme temperature exposures. 4
Limit frequent hot‑water washing and exposure to other skin irritants. 5

Re‑assessment after 2–4 weeks of therapy is recommended to evaluate clinical response and adjust treatment as needed. 5

Low‑dose isotretinoin (20–30 mg daily) is reserved for refractory or severe disease and must not be combined with tetracyclines because of a reported risk of cerebral edema. 5
Topical benzoyl‑peroxide–containing anti‑acne products should be avoided, as they can exacerbate rosacea‑related irritation. 5